ClinicalTrials.gg
Not yet recruitingNCT07942662Updated Nov 17, 2026

Intrathecal Morphine 200 Micrograms Versus 450 Micrograms After Major Open Urologic Surgery

A Phase 4 interventional study of Intrathecal Morphine 450 Micrograms and Paracetamol in Postoperative Pain, sponsored by Clinical Hospital Centre Zagreb. Not yet recruiting at 1 site in Croatia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Clinical Hospital Centre Zagreb · Phase 4, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Pain, Postoperative with a site in Croatia — 7 open to participants now, 7 under way, 1 of them phase 3. Pain, Postoperative · Croatia.

Planned enrollment
Largest of 16
130 · median 66
Started
2026
with 1 other
Phase 4
5 of 18
3 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Clinical Hospital Centre Zagreb

Among the 18 studies in Pain, Postoperative with a site in Croatia, this one has the largest planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 4, and was the 18th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 18 studies in Pain, Postoperative with a site in Croatia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Croatia have not opened yet or have stopped. Only those recruiting at a site in Croatia →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Pain, Postoperative with a site in Croatia, or all of them as a file.
02

Study summary

This randomized clinical trial will compare two active doses of preservative-free intrathecal morphine (200 micrograms and 450 micrograms) for postoperative analgesia in adults undergoing major elective open urologic surgery. Participants will be assigned by chance in a 1:1 ratio to receive one of the two intrathecal morphine doses before general anesthesia. Both groups will receive the same standardized non-opioid analgesia, the same pain-assessment-guided intravenous sufentanil rescue and infusion protocol, and the same postoperative monitoring and safety measures.

The main outcome is the total amount of intravenous sufentanil administered from admission to the intensive care unit through the next 24 hours. Other outcomes include pain scores, time to first rescue sufentanil, initiation of continuous sufentanil infusion, clinically significant sedation, opioid-related respiratory depression, nausea and/or vomiting, pruritus, and clinically significant hypotension.

The study will test whether increasing the intrathecal morphine dose from 200 micrograms to 450 micrograms provides a clinically relevant additional reduction in postoperative systemic opioid requirements without an evident increase in clinically relevant adverse effects.

Read the detailed description

This prospective, single-center, randomized, active-controlled, parallel-group superiority trial compares single-shot preservative-free intrathecal morphine 200 micrograms versus 450 micrograms in adults undergoing elective major open urologic surgery. Eligible operations are open radical cystectomy, open simple, partial or radical nephrectomy, open nephroureterectomy, and open retroperitoneal lymphadenectomy for a uro-oncologic indication. Benign and malignant indications are eligible for nephrectomy. Minimally invasive surgery and prostatectomy are excluded.

Participants are randomized 1:1 on the morning of surgery after eligibility and consent verification, using computer-generated variable blocks of sizes 4 and 6 stratified by planned open radical cystectomy versus all other eligible major open urologic procedures. The operating-room anesthesiologist knows the allocation and prepares/administers the assigned intrathecal morphine dose before general anesthesia; participants, postoperative ICU care providers involved in analgesia decisions, and formal outcome assessors are masked. Both intrathecal doses are prepared in the same final volume of 2.5 mL without local anesthetic or another intrathecal adjuvant.

Both groups receive identical multimodal non-opioid analgesia: intravenous paracetamol 1 g for a total of three doses and intravenous metamizole 2.5 g for a total of two doses, in each case counting the first dose administered immediately before transfer from operating room to ICU. Subsequent doses are timed from the actual first administration. Intraoperative opioid management is not standardized and is recorded separately.

T0 is the actual time of ICU admission. From T0 through T0+24 hours, rescue intravenous sufentanil is guided by pain at rest (NRS at rest >=4) or CPOT >=3 when reliable self-report is not possible. The algorithm uses 5-microgram boluses reassessed after 10 minutes; persistent pain after two boluses leads to initiation or increase of infusion by 5 micrograms/hour (protocol infusion levels: 0, 5, 10, 15 and 20 micrograms/hour). Reassess 30 minutes after infusion initiation/escalation. Stepwise de-escalation by 5 micrograms/hour is considered only after six consecutive hours of confirmed adequate analgesia without rescue boluses, infusion escalation or physician rescue for uncontrolled pain, with clinical conditions satisfied; reassess 30 minutes after reduction. Safety-driven changes or physician-directed rescue are permitted when clinically needed. The rescue protocol ends at T0+24 hours and is not continued on the urology ward.

The primary outcome is total protocol-defined intravenous sufentanil delivered between T0 and T0+24 hours, including eligible rescue boluses, infusion exposure and physician-directed sufentanil rescue/escalation, but excluding intraoperative and transport opioids, opioids used for anesthesia during unplanned reoperation, and other opioid drugs. Secondary measures include pain at rest at T6 (+/-1 hour), pain at rest and during one standardized cough at T24 (+/-2 hours), time to first rescue sufentanil, initiation of continuous infusion, and prespecified clinical safety outcomes. Cough pain alone is not a trigger for protocol rescue.

The operational efficacy target is 120 evaluable treated participants (60 per arm). The primary operational population includes randomized participants who receive assigned intrathecal morphine, undergo an eligible index operation and have an evaluable 24-hour primary endpoint. Participants excluded by predefined non-evaluability events remain in the randomized study log and are replaced to reach the evaluable target; consequently, total enrollment/randomizations may exceed 120. Statistical analysis details will be specified separately in the statistical analysis plan.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Intrathecal Morphine
  • Intravenous Sufentanil
  • Opioid-Sparing Analgesia
  • Postoperative Opioid Consumption
  • Major Open Urologic Surgery
  • Dose Comparison
  • Dose Optimization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • (ASA) Physical Status I-III.
  • Scheduled for one of the following elective major open urologic surgical procedures:
  • Open radical cystectomy;
  • Open partial nephrectomy;
  • Open simple nephrectomy;
  • Open radical nephrectomy;
  • Open nephroureterectomy;
  • Open retroperitoneal lymphadenectomy for a uro-oncologic indication.
  • Both benign and malignant indications are eligible for nephrectomy.
  • Planned postoperative admission to the intensive care unit for at least 24 hours.
  • Able to understand the study and provide written before randomization.
  • Able to understand and use a 0-10 Numeric Rating Scale (NRS) for pain when awake and able to communicate reliably.

Exclusion criteria

Exclusion Criteria:

  • ASA Physical Status IV or V.
  • Any to neuraxial puncture, including infection at the puncture site, active systemic infection or sepsis, coagulopathy or hemostatic disorder, or antiplatelet or anticoagulant treatment incompatible with the required neuraxial safety intervals.
  • Known or other absolute contraindication to morphine, an of the intrathecal morphine preparation, or sufentanil.
  • Severe renal failure requiring renal replacement therapy.
  • Severe hepatic insufficiency, decompensated liver disease, or clinically significant hepatic dysfunction considered incompatible with safe application of the protocol.
  • Severe respiratory insufficiency or uncontrolled obstructive sleep apnea considered unacceptably high risk despite planned ICU monitoring.
  • Inability to provide written or persistent inability to understand and use the Numeric Rating Scale when awake.
  • Current scheduled or routine daily opioid therapy for chronic pain, or active opioid dependence or opioid use disorder.
  • Any other specifically documented condition that makes neuraxial puncture or either randomized analgesic strategy unsafe, or prevents reliable completion of the 24-hour primary outcome assessment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Intrathecal Morphine 450 Micrograms

    Participants will receive a single preoperative dose of preservative-free intrathecal morphine 450 micrograms before induction of general anesthesia. They will also receive the common standardized postoperative analgesic regimen used in both study arms, including intravenous paracetamol, intravenous metamizole, and the protocol-defined pain-assessment-guided intravenous sufentanil rescue and infusion algorithm.

    Drug: Intrathecal Morphine 450 Micrograms · Drug: Paracetamol · Drug: Metamizole · Drug: Sufentanil

  • Active comparator
    Intrathecal Morphine 200 Micrograms

    Participants will receive a single preoperative dose of preservative-free intrathecal morphine 200 micrograms before induction of general anesthesia. They will also receive the common standardized postoperative analgesic regimen used in both study arms, including intravenous paracetamol, intravenous metamizole, and the protocol-defined pain-assessment-guided intravenous sufentanil rescue and infusion algorithm.

    Drug: Paracetamol · Drug: Metamizole · Drug: Sufentanil · Drug: Intrathecal Morphine 200 Micrograms

Interventions

  • DrugIntrathecal Morphine 450 Micrograms

    Single intrathecal injection of 450 micrograms preservative-free morphine, prepared in a final volume of 2.5 mL, before induction of general anesthesia; no intrathecal local anesthetic or adjunct. Allowed puncture levels: L2-L3, L3-L4, L4-L5.

    Also known as: Morphine sulfate, preservative-free morphine

  • DrugParacetamol

    Paracetamol 1 g will be administered intravenously three times during the initial perioperative 24-hour period, approximately every 8 hours. The first dose will be given immediately before transfer from the operating room to the ICU. Subsequent doses will be timed from the actual first dose. A dose may be delayed or omitted for a documented clinical contraindication or safety reason.

    Also known as: Acetaminophen

  • DrugMetamizole

    Metamizole 2.5 g will be administered intravenously twice during the initial perioperative 24-hour period, approximately every 12 hours. The first dose will be given immediately before transfer from the operating room to the ICU. Subsequent doses will be timed from the actual first dose. A dose may be delayed or omitted for a documented clinical contraindication or safety reason.

    Also known as: Dipyrone

  • DrugSufentanil

    From actual ICU admission (T0) to T0+24 hours, IV sufentanil rescue follows the same pain-triggered algorithm in both arms: NRS at rest \>=4 or CPOT \>=3; 5-microgram IV bolus, reassessment after 10 minutes, second 5-microgram bolus when indicated, and infusion start/escalation by 5 micrograms/hour when the trigger persists. Infusion rates are 0, 5, 10, 15 and 20 micrograms/hour; reassess 30 minutes after initiation/escalation. Following six consecutive hours of confirmed adequate analgesia without rescue or escalation, de-escalate by one 5-microgram/hour step if clinical criteria are met, followed by reassessment at 30 minutes. Physician-directed safety deviations are permitted. The study rescue window stops exactly at T0+24 hours.

  • DrugIntrathecal Morphine 200 Micrograms

    Single intrathecal injection of 200 micrograms preservative-free morphine, prepared in a final volume of 2.5 mL, before induction of general anesthesia; no intrathecal local anesthetic or adjunct. Allowed puncture levels: L2-L3, L3-L4, L4-L5.

    Also known as: Morphine sulfate, preservative-free morphine

06

What researchers measure

Primary outcomes

  1. Cumulative Intravenous Sufentanil Consumption During the First 24 Hours After ICU Admission

    The primary outcome is the cumulative dose of protocol-defined intravenous sufentanil administered from actual intensive care unit admission (T0) through T0+24 hours, regardless of intubation status. The total includes eligible rescue boluses, continuous infusion exposure, and physician-directed sufentanil rescue or escalation during this interval. Intraoperative and transport opioids, opioids administered for anesthesia during unplanned reoperation, and other opioid drugs are excluded. The cumulative dose will be calculated from time-stamped medication records and expressed in micrograms. Higher values indicate greater postoperative sufentanil consumption.

    Time frame: From intensive care unit admission (T0) through 24 hours after intensive care unit admission

Secondary outcomes

  1. Time to First Rescue Intravenous Sufentanil Dose

    Time from ICU admission (T0) to administration of the first protocol-defined rescue intravenous sufentanil dose. Participants who do not receive rescue sufentanil during T0-T24 will have no rescue event during the observation window.

    Time frame: From intensive care unit admission (T0) through 24 hours after intensive care unit admission

  2. Numeric Rating Scale (NRS) Pain Score at Rest 6 Hours After ICU Admission

    Pain intensity at rest will be assessed using an 11-point Numeric Rating Scale (NRS) ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. The actual assessment date and time will be recorded. If the participant cannot be assessed reliably, the outcome will be recorded as not assessable rather than assigned a score of zero.

    Time frame: 6 hours after actual intensive care unit admission (T6), with an acceptable assessment window of ±1 hour.

  3. Numeric Rating Scale (NRS) Pain Score at Rest 24 Hours After ICU Admission

    Pain intensity at rest will be assessed using an 11-point Numeric Rating Scale (NRS) ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. The actual assessment date and time will be recorded. If the participant cannot be assessed reliably, the outcome will be recorded as not assessable rather than assigned a score of zero.

    Time frame: 24 hours after actual intensive care unit admission (T24), with an acceptable assessment window of ±2 hours.

  4. Numeric Rating Scale (NRS) Pain Score During Standardized Cough 24 Hours After ICU Admission

    Pain intensity during one standardized cough will be assessed using an 11-point Numeric Rating Scale (NRS) ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. The participant will be instructed to cough once as strongly as possible, and the pain score during coughing will then be recorded. The actual assessment date and time will be documented. If the participant cannot be assessed reliably, the outcome will be recorded as not assessable rather than assigned a score of zero.

    Time frame: 24 hours after actual intensive care unit admission (T24), with an acceptable assessment window of ±2 hours.

  5. Initiation of Continuous Intravenous Sufentanil Infusion During the First 24 Hours After ICU Admission

    Whether a continuous intravenous sufentanil infusion was initiated at any time from intensive care unit admission (T0) through T0 + 24 hours. The outcome will be classified as yes if at least one continuous sufentanil infusion interval was started during the observation window and as no if no continuous infusion was initiated. Initiation of a continuous sufentanil infusion in either study arm is a protocol-defined response to pain and is not classified as treatment failure.

    Time frame: From intensive care unit admission (T0) through 24 hours after intensive care unit admission

  6. Participants With Clinically Significant Opioid-Related Respiratory Depression During the First 24 Hours After ICU Admission

    Number of participants with at least one respiratory event considered related or possibly related to opioid exposure and meeting at least one of the following criteria: respiratory rate below 8 breaths per minute accompanied by a documented clinical intervention; naloxone administration for suspected opioid-related respiratory depression; manual ventilation; non-invasive ventilation; unplanned intubation or reintubation because of suspected opioid effect; or unplanned prolongation of invasive ventilation because of suspected opioid effect. Isolated oxygen desaturation or an increase in supplemental oxygen alone will not qualify as clinically significant opioid-related respiratory depression.

    Time frame: From intensive care unit admission (T0) through 24 hours after intensive care unit admission

  7. Participants With Clinically Significant Sedation During the First 24 Hours After ICU Admission

    Number of participants with at least one clinically significant sedation event from intensive care unit admission (T0) through T0 + 24 hours. A qualifying event is defined as a Richmond Agitation-Sedation Scale score of -3 to -5, if formally assessed, or an equivalent clinical state in which the participant cannot be easily aroused or cannot maintain wakefulness. A participant who is sleeping but readily arousable and able to maintain wakefulness does not meet the definition.

    Time frame: From intensive care unit admission (T0) through 24 hours after intensive care unit admission

  8. Participants With Postoperative Nausea and/or Vomiting During the First 24 Hours After ICU Admission

    Number of participants with at least one episode of nausea, vomiting, or both from intensive care unit admission (T0) through T0 + 24 hours.

    Time frame: From intensive care unit admission (T0) through 24 hours after intensive care unit admission

  9. Participants With Pruritus During the First 24 Hours After ICU Admission

    Number of participants with at least one documented episode of pruritus from intensive care unit admission (T0) through T0 + 24 hours.

    Time frame: From intensive care unit admission (T0) through 24 hours after intensive care unit admission

  10. Participants With Clinically Significant Hypotension During the First 24 Hours After ICU Admission

    Number of participants with at least one episode of clinically significant hypotension from intensive care unit admission (T0) through T0 + 24 hours. Clinically significant hypotension is defined as a mean arterial pressure below 65 mmHg and/or a systolic blood pressure below 90 mmHg requiring vasopressor treatment and/or an intravenous fluid bolus administered for hypotension. The event is not automatically attributed to opioid exposure.

    Time frame: From intensive care unit admission (T0) through 24 hours after intensive care unit admission

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data sharing is not planned.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Oct 2029, 34 months later.

Of 532 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 34 months is above that.

Counting every sponsor, half of 542 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 2026
Primary completionEst.
Oct 8, 2029
CompletionEst.
Oct 8, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942662
Lead sponsor
Clinical Hospital Centre Zagreb
Responsible party
Eleonora Goluza (Assistant Professor; Specialist in Anesthesiology, Reanimatology and Intensive Care Medicine; Subspecialist in Intensive Care Medicine; Head of Department, Clinical Hospital Centre Zagreb) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 2026 (estimated)
Primary completion
Oct 8, 2029 (estimated)
Completion
Oct 8, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Eleonora Goluža
principal investigator · Clinical Hospital Centre Zagreb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion